Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 16/20 | 0.59 |
| ▸ | ITGB2 | P05107 | 15/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.59 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13813603 | 0.94 | ITGAL (0.67) | ITGALITGB2ICAM1PRMT5WDR77 | |
| SCHEMBL23176585 | 0.92 | ITGAL (0.59) | ITGALITGB2ICAM1PRMT5WDR77 | |
| SCHEMBL17991461 | 0.86 | ITGAL (0.76) | ITGALITGB2ICAM1 | |
| SCHEMBL16731604 | 0.79 | ITGAL (0.68) | ITGALITGB2ICAM1 | |
| SCHEMBL17991454 | 0.77 | ITGAL (0.65) | ITGALITGB2ICAM1 | |
| SCHEMBL22296843 | 0.76 | ITGAL (0.64) | ITGALITGB2ICAM1 | |
| SCHEMBL19158522 | 0.74 | ITGAL (0.77) | ITGALITGB2ICAM1 | |
| SCHEMBL16307479 | 0.72 | ITGB2 (0.69) | ITGALITGB2ICAM1 | |
| SCHEMBL4755996 | 0.72 | ITGB2 (0.80) | ITGALITGB2ICAM1 | |
| SCHEMBL12169926 | 0.71 | ITGAL (0.65) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3167886-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | NOVARTIS AG (CH) | 2020-08-05 | — | — | EP | disclosed |